

### Ensaio do promotor Indústria Farmacêutica

#### Ensaio Clínico Realizados | Intervencionais | 2022

##### Cardiologia

Nome do ensaio	Promotor	Título	Investigador Principal
20103 Finearts-HF	Bayer	A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction $\geq$ 40%. (LVEF $\geq$ 40%)	Luís Santos
20170625 - Vesalius	Amgen	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke	Manuela Vieira
AEGIS-II	CSL BEHRING	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome	Luís Santos
Quadrixam / CL3-05179-002	Servier	Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combination of perindopril 10 mg, indapamide 2.5 mg and amlodipine 5 or 10 mg in patients with uncontrolled resistant essential hypertension. An international, multicentre, randomised, double-blind, 16-week study.	Mesquita Bastos

##### Cirurgia

Nome do ensaio	Promotor	Título	Investigador Principal
D-PLEX 312	PolyPid	Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treatment Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection	Joana Noronha

##### Endocrinologia

Nome do ensaio	Promotor	Título	Investigador Principal
Focus - NN9535-4352	Novo Nordisk	Long-term effects of semaglutide on diabetic retinopathy in patients with type 2 diabetes	Joana Guimarães

##### Hematologia

Nome do ensaio	Promotor	Título	Investigador Principal
KRT-232-101	Kartos Therapeutics	A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment	Fernando Silva
BO42162 / Commodore 2	Roche	A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors	Fernando Silva

### Ensaios do promotor Indústria Farmacêutica

#### Infeciologia

Nome do ensaio	Promotor	Título	Investigador Principal
DOMINO - 208379 - GSK3640254	ViiV Healthcare UK Limited	Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcriptase inhibitors, in HIV-1 infected antiretroviral treatment-naive adults	Daniel Coutinho

#### Medicina Interna

Nome do ensaio	Promotor	Título	Investigador Principal
ESSENCE3 (NN9931-4553)	Novo Nordisk	The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis	Rosa Jorge
Regenerate	Intercept	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Rosa Jorge
Clover - B5091007	Pfizer	A phase 3, placebo-controlled, randomized, observer-blinded Study to evaluate the efficacy, safety, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and Older	Rosa Jorge

#### Nefrologia

Nome do ensaio	Promotor	Título	Investigador Principal
BI 1378-0005	Boehringer	A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney disease	Nuno Figueiredo
EX6018-4758 - ZEUS	Novo Nordisk	Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic disease, stage 3-4 kidney disease, and chronic inflammation	Nuno Figueiredo
BI 1366-0005	Boehringer	Ensaio aleatorizado, em dupla ocultação (dentro dos grupos de dose), controlado por placebo, de grupos paralelos para investigar os efeitos de diferentes doses orais de BI 685509, administradas durante 20 semanas, na redução da razão albumina/creatinina na urina, em doentes com doença renal diabética.	Nuno Figueiredo
TRCA - 303 (VALOR-CKD)	Tricida, Inc	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Chronic Kidney Disease (CKD) Progression and Long-Term Safety of TRC101 in Subjects with Metabolic Acidosis (MA)	Nuno Figueiredo
BI 1366-0022	Boehringer	Ensaio aleatorizado, em dupla ocultação (dentro dos grupos de dose), controlado por placebo, de grupos paralelos para investigar os efeitos de diferentes doses orais de BI 685509, administradas durante 20 semanas, na redução da razão albumina/creatinina na urina, em doentes com doença renal não diabética.	Nuno Figueiredo

**Ensaios do promotor Indústria Farmacêutica**
**Neurologia**

Nome do ensaio	Promotor	Título	Investigador Principal
BIA-91067-404	Bial	Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with motor fluctuations and associated pain	Beatriz Santiago

**Otorrinolaringologia**

Nome do ensaio	Promotor	Título	Investigador Principal
LPS16747 Everest	Sanofi	A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients	Luísa Azevedo
Orion - EFC16723	Sanofi	A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without polyposis (CRSsNP)	Luísa Azevedo

**Pneumologia**

Nome do ensaio	Promotor	Título	Investigador Principal
EFC16819 / AERIFY 2	Sanofi	Randomized, double-blind, placebo-controlled, parallelgroup Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)	Gilberto Teixeira
Morpheo - LPS16677	Sanofi	A randomized double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma	Bárbara Rodrigues
ASPEN - INS1007-301	Insmad Incorporated	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis	Lília Andrade
Notus - EFC15805	Sanofi	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation	João Cravo

**Urologia**

Nome do ensaio	Promotor	Título	Investigador Principal
17000139BLC2001 / Sunrise	Janssen	Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab or Alone in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guerin who are Ineligible for or Elected Not to Undergo Radical Cystectomy	António Patricio

Fonte: BlueClinical em 13/02/2023

## Ensaaios do promotor Indústria Farmacêutica

## Ensaaios Clínicos | Estudos Observacionais Realizados | 2022

## Cardiologia

Nome do estudo	Promotor	Título	Investigador Principal
DSE-EDO-04-14-EU ETNA	Daiichii Sankyo	Estudo não interventivo sobre o tratamento com edoxabano na prática clínica de rotina em doentes com fibrilação auricular não valvular	Luís Santos

## Hematologia

Nome do estudo	Promotor	Título	Investigador Principal
PAIS - 54179060CLL4020	Janssen	Analysis of Stereotyped B-cell Receptors Frequencies Among Portuguese 'De Novo' Diagnosed Chronic Lymphocytic Leukaemia Patients	Gisela Ferreira
MRDeep	Janssen	Prevalence of minimal residual disease (MRD) in patients treated for Multiple Myeloma (MM) who reach complete response and are currently on 2nd or 3rd line of therapy for MM	Gisela Ferreira

## Neurologia

Nome do estudo	Promotor	Título	Investigador Principal
Top	Biogen	Tysabri® observational program	José Rente

## Urologia

Nome do estudo	Promotor	Título	Investigador Principal
CaPa - 56021927PCR4015	Janssen	Characterization of Castrate-Resistant Prostate Cancer patients followed in Urology Department of Portuguese hospitals	António Patrício

Fonte: BlueClinical em 13/02/2023